#None #Menarini Group #Bofanglutide #Gan & Lee

Overview of the Partnership

Gan & Lee Pharmaceuticals has officially announced a significant partnership with the Menarini Group to enhance the development and market access of its innovative product, Bofanglutide. This drug, currently in clinical trials, targets conditions related to obesity, which is a growing concern across Europe. The exclusive licensing agreement between Gan & Lee and Menarini marks a crucial milestone in both companies’ strategic plans to expand their presence in the metabolic disease sector.

Financial Terms and Market Scope

Under the terms of the agreement, Gan & Lee is set to receive an upfront payment of €62 million, with potential milestone payments totaling up to €664 million, along with royalties in the double-digit percentage range based on net sales within the licensed territory. Menarini will be responsible for regulatory submissions and marketing across 39 countries, including all EU member states, the UK, Switzerland, Norway, Iceland, Liechtenstein, and the Balkans. This collaboration is particularly impactful as it allows for swift entry into highly regulated markets, leveraging Menarini's established foothold and expertise.

Product Details

Bofanglutide (development code GZR18) is classified as a GLP-1 receptor agonist, administered via subcutaneous injection every two weeks. This biweekly dosing cadence is innovative, reducing the frequency of administration compared to other GLP-1 medications that are typically delivered weekly. Clinical studies conducted in China, as well as a phase-2 trial in the U.S., have shown positive results, meeting primary endpoints related to weight loss and exhibiting a safety profile consistent with that of other drugs in the class.

Strategic Goals and Future Development

Dr. Wei Chen, Chairman and CEO of Gan & Lee, emphasized that this partnership not only paves the way for Bofanglutide's entry into the European market but also marks an important step in transitioning Gan & Lee from a leader in the insulin sector to a global innovator addressing metabolic diseases. He highlighted the commitment to harness the strengths of both companies—Gan & Lee's prowess in clinical development and Menarini's capabilities in regulatory strategies and commercial execution—to provide alternative therapeutic options for millions suffering from obesity and related conditions.

Elcin Barker Ergun, Group CEO of Menarini, expressed excitement about collaborating with Gan & Lee to successfully execute further regulatory studies, aiming to bring this new treatment to patients in their extensive distribution regions. The preliminary results from clinical studies show promise in terms of weight reduction and secondary metabolic benefits, making the biweekly dosing an appealing differentiator in the market.

Conclusion

This partnership not only enhances Gan & Lee's geographical reach but also represents a strategic commitment for Menarini to expand its role in the metabolic disease area. By working closely together, both companies aim to optimize the development of Bofanglutide and ensure access for patients in need of innovative therapies.
More than just a business collaboration, this agreement signifies a shared vision for addressing the pressing health issues associated with obesity and diabetes, and it underscores both companies' dedication to advancing patient care in the field of metabolic disorders. As Gan & Lee continues to pursue its global development plans, including a robust phase-3 clinical program, the future looks promising for Bofanglutide’s success in the European market.